

Mavorixafor

Catalog No: tcsc0352



Available Sizes

Size: 2mg

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

558447-26-0

Formula:

$C_{21}H_{27}N_5$

Pathway:

GPCR/G Protein; Immunology/Inflammation; Anti-infection

Target:

CXCR; CXCR; HIV

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

AMD-070

Observed Molecular Weight:

349.47


Product Description

Mavorixafor (AMD-070) is a potent, selective and orally available **CXCR4** antagonist, with an **IC₅₀** value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an **IC₅₀** of 1 and 9 nM, respectively.

IC50 & Target: IC50: 13 nM (¹²⁵I-SDF-CXCR4), 1 nM (HIV-1 (NL4.3 strain), in MT-4 cells), 9 nM (HIV-1 (NL4.3 strain), in PBMCs)^[1]

In Vitro: Mavorixafor (AMD-070) is a potent and orally available CXCR4 antagonist, with an IC₅₀ value of 13 nM against CXCR4 ¹²⁵I-SDF binding, and also inhibits the replication of T-tropic HIV-1 (NL4.3 strain) in MT-4 cells and PBMCs with an IC₅₀ of 1 and 9 nM, respectively. Mavorixafor (AMD-070) shows no effect on other chemokine receptors (CCR1, CCR2b, CCR4, CCR5, CXCR1, and CXCR2) ^[1]. Mavorixafor (AMD-070) (6.6 μM) significantly suppresses the anchorage-dependent growth, the migration and matrigel invasion of the B88-SDF-1 cells^[2].

In Vivo: Mavorixafor (AMD-070) (2 mg/kg, p.o.) significantly reduces the number of metastatic lung nodules in mice, and lowers the expression of human Alu DNA in mice, without body weight loss^[2].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!